Loading clinical trials...
Loading clinical trials...
A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
Conditions
Interventions
Baricitinib
TNF Inhibitor
Locations
261
United States
Arizona Arthritis & Rheumatology Research, PLLC
Flagstaff, Arizona, United States
Arthrocare, Arthritiscare & Research Pc
Gilbert, Arizona, United States
Arizona Arthritis & Rheumatology Research, PLLC
Glendale, Arizona, United States
Arizona Arthritis & Rheumatology Research, PLLC
Mesa, Arizona, United States
Hope Research Institute
Peoria, Arizona, United States
Hope Research Institute
Phoenix, Arizona, United States
Start Date
April 25, 2019
Primary Completion Date
May 28, 2025
Completion Date
May 28, 2025
Last Updated
July 22, 2025
NCT06329401
NCT07048197
NCT07484243
NCT06647069
NCT06841562
NCT07268326
Lead Sponsor
Eli Lilly and Company
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions